SUVEN Life Sciences

Communication to investors
Mar 2012

Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

FINANCIAL QUICK VIEW
Quarter 4 – Mar 2012

- Growth in revenue 34.30%
- Growth in PAT 137.26%
- Growth in EBIDTA 130.07%
- Growth in Pre-R&D EBIDTA 61.12%
- Increase in R&D costs 10.22%
- R&D cost on revenue 13.54%


FINANCIAL QUICK VIEW
Year ending – Mar 2012

- Growth in revenue 35.63%
- Growth in PAT 49.26%
- Growth in EBIDTA 70.27%
- Growth in Pre-R&D EBIDTA 27.30%
- Increase in R&D costs 6.87%
- R&D cost on revenue 16.18%


MAJOR PROFITABILITY RATIOS

	Q4 Mar 12	Q4 Mar 11	YE Mar 12	YE Mar 11
PAT to Income	13.31%	7.53%	7.54%	6.86%
EBIDTA to Income	20.87%	12.18%	12.25%	9.76%
Cash Flow to Income	15.51%	10.46%	10.24%	10.45%
Pre-R&D EBITDA to Income	34.41%	28.68%	28.43%	30.29%

INCOME COMPARISON




PROFIT COMPARISON




PAT for year ending Mar12 is after provision for MTM of Rs. 34.80 Million towards forward contracts due to exchange fluctuation


EBIDTA COMPARISON



PRE-R&D EBIDTA



PRE-R&D CASHFLOW



Updates for the quarter

- During the quarter there were major qualitative achievements with the grant of 3 product patents to Suven's drug discovery pipeline which consists of 13 molecules out of which twelve (12) molecules currently in pre-clinical stage of development in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.